2006 AIChE Annual Meeting
(586f) Validation of a Model Predicting the Influence of Cyclodextrins on Oral Bioavailability: Comparison with in Vitro and in Vivo Data
Authors
In vitro experiments were conducted to test the model predictions of the influence of CD on key processes in the GI tract environment. Dissolution and absorption kinetics of low solubility drugs that form complexes with CD2(Naproxen and Nifedipine) were tested in the presence and absence of CD (β-CD) in a simulated gastrointestinal environment (37ºC, well-mixed). Dissolution test results in simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) fit simulation results with over 95% confidence. Absorption experiments were conducted with Naproxen, a weak acid, in a diffusion cell apparatus with a Caco-2 monolayer separating the two diffusion chambers. Due to its pKa (4.84), Naproxen is protonated in Kreb's buffer (pH = 7.4) and thus has higher solubility than the unionized form. NCPM model simulations predict that CD has a negative effect on absorption of high solubility drugs as it reduces the free drug concentration. In absorption experiments with Naproxen, the negative effect of CD on drug absorption was also observed. For a dose of 0.5 mgA/ml, the absorption of drug was reduced from 5.42 % in the absence of CD to 2.10 % in the presence of CD 2 hours post-dosing. To enable comparison of simulation predictions with in vivo drug bioavailability data obtained from the literature, a pharmacokinetic (PK) model was incorporated into the NCPM model. Comparison of model predictions with in vitro and in vivo data are being used to demonstrate the model's ability to predict the influence of CD on oral drug absorption and validate utility of modeling for rational dosage form design.
1. Stella VJ, Rajewski RA 1997. Cyclodextrins: their future in drug formulation and delivery. Pharmaceutical Research 14(5):556-567. 2. Erden N, Celebi N 1988. A study of the inclusion complex of naproxen with β-cyclodextrin. International Journal of Pharmaceutics 48(1-3):83-89.